What have we learnt so far from COVID-19?

被引:13
|
作者
Doherty, Peter C. [1 ]
机构
[1] Univ Melbourne, Dept Microbiol & Immunol, Melbourne, Vic, Australia
关键词
D O I
10.1038/s41577-021-00498-y
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
While COVID-19 shows us the enormous power of modern molecular medicine, it also reminds us of the basic contradictions and limitations of the human condition. As it is highly likely we will experience further such events through the twenty-first century, we should regard COVID-19 as a training run for something that could be much worse, and organize our governance, global interactions, institutions and practices accordingly.
引用
收藏
页码:67 / 68
页数:2
相关论文
共 50 条
  • [21] Organ manifestations of COVID-19: what have we learned so far (not only) from autopsies?
    Jonigk, Danny
    Werlein, Christopher
    Acker, Till
    Aepfelbacher, Martin
    Amann, Kerstin U.
    Baretton, Gustavo
    Barth, Peter
    Bohle, Rainer M.
    Buettner, Andreas
    Buettner, Reinhard
    Dettmeyer, Reinhard
    Eichhorn, Philip
    Elezkurtaj, Sefer
    Esposito, Irene
    Evert, Katja
    Evert, Matthias
    Fend, Falko
    Gassler, Nikolaus
    Gattenloehner, Stefan
    Glatzel, Markus
    Goebel, Heike
    Gradhand, Elise
    Hansen, Torsten
    Hartmann, Arndt
    Heinemann, Axel
    Heppner, Frank L.
    Hilsenbeck, Julia
    Horst, David
    Kamp, Jan C.
    Mall, Gita
    Maerkl, Bruno
    Ondruschka, Benjamin
    Pablik, Jessica
    Pfefferle, Susanne
    Quaas, Alexander
    Radbruch, Helena
    Roecken, Christoph
    Rosenwald, Andreas
    Roth, Wilfried
    Rudelius, Martina
    Schirmacher, Peter
    Slotta-Huspenina, Julia
    Smith, Kevin
    Sommer, Linna
    Stock, Konrad
    Stroebel, Philipp
    Strobl, Stephanie
    Titze, Ulf
    Weirich, Gregor
    Weis, Joachim
    VIRCHOWS ARCHIV, 2022, 481 (02) : 139 - 159
  • [22] KEY CHALLENGES IN MODELLING AN EPIDEMIC - WHAT HAVE WE HAVE LEARNED FROM THE COVID-19 EPIDEMIC SO FAR
    Erzen, Ivan
    Kamensek, Tina
    Fosnaric, Miha
    Zibert, Janez
    ZDRAVSTVENO VARSTVO, 2020, 59 (03): : 117 - 119
  • [23] COVID-19 vaccine challenges: What have we learned so far and what remains to be done?
    Forman, Rebecca
    Shah, Soleil
    Jeurissen, Patrick
    Jit, Mark
    Mossialos, Elias
    HEALTH POLICY, 2021, 125 (05) : 553 - 567
  • [24] Smoking and COVID-19: What we know so far
    Shastri, Madhur D.
    Shukla, Shakti D.
    Chong, Wai Chin
    Kc, Rajendra
    Dua, Kamal
    Patel, Rahul P.
    Peterson, Gregory M.
    O'Toole, Ronan F.
    RESPIRATORY MEDICINE, 2021, 176
  • [25] Eosinopenia in COVID-19: What we missed so far?
    Davido, Benjamin
    Partouche, Bethsabee
    Jaffal, Karim
    de Truchis, Pierre
    Herr, Marie
    Pepin, Marion
    JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION, 2021, 54 (05) : 1006 - 1007
  • [26] COVID-19 and cancer: what we know so far
    Sidaway, Peter
    NATURE REVIEWS CLINICAL ONCOLOGY, 2020, 17 (06) : 336 - 336
  • [27] COVID-19 and Myositis: What We Know So Far
    Saud, Ahmad
    Naveen, R.
    Aggarwal, Rohit
    Gupta, Latika
    CURRENT RHEUMATOLOGY REPORTS, 2021, 23 (08)
  • [28] COVID-19 and cancer: what we know so far
    Peter Sidaway
    Nature Reviews Clinical Oncology, 2020, 17 : 336 - 336
  • [29] COVID-19 and Myositis: What We Know So Far
    Ahmad Saud
    R Naveen
    Rohit Aggarwal
    Latika Gupta
    Current Rheumatology Reports, 2021, 23
  • [30] COVID-19: What we've learned so far
    Williams, Ged
    Canon-Montanez, Wilson
    REVISTA CUIDARTE, 2020, 11 (02)